US2021308099A1PendingUtilityA1

Methods and compositions for treatment of alzheimer's disease and other neurodegenerative disorders

66
Assignee: SYNAPTOGENIX INCPriority: May 18, 2018Filed: Jun 18, 2021Published: Oct 7, 2021
Est. expiryMay 18, 2038(~11.8 yrs left)· nominal 20-yr term from priority
Inventors:Daniel L. Alkon
A61K 31/365A61K 38/00A61K 9/0019A61P 25/28C07K 14/49
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.

Claims

exact text as granted — not AI-modified
1 .- 14 . (canceled) 
     
     
         15 . A method for inducing synaptogenesis in a subject having synaptic loss, the method comprising orally administering to the subject a therapeutically effective amount of a synaptic growth factor activating compound that functions as a PKC activator to result in an increase in synaptogenesis in said subject, wherein the synaptic growth factor activating compound is administered for the first two doses at about 24 micrograms followed by four consecutive doses of about 20 micrograms each. 
     
     
         16 . The method of  claim 15 , wherein the synaptic growth factor is selected from the group consisting of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and insulin-like growth factor (IGF). 
     
     
         17 . The method of  claim 15 , wherein the method increases BDNF levels. 
     
     
         18 . The method of  claim 15 , wherein the method prevents cognitive loss. 
     
     
         19 . The method of  claim 15 , wherein the method restores lost synapses. 
     
     
         20 . The method of  claim 15 , wherein the synaptic growth factor activating compound is combined with a non-growth factor PKC activator, wherein PKC is protein kinase C. 
     
     
         21 . The method of  claim 15 , wherein the subject is not administered an N-methyl-D-aspartate (NMDA) receptor antagonist. 
     
     
         22 . The method of  claim 15 , wherein said four consecutive doses are administered every other week. 
     
     
         23 . The method of  claim 15 , wherein said first two doses at about 24 micrograms are followed by at least four consecutive doses of about 20 micrograms each. 
     
     
         24 . A method for inducing synaptogenesis in a subject having synaptic loss, the method comprising administering to the subject a therapeutically effective amount of a synaptic growth factor activating compound that functions as a PKC activator to result in an increase in synaptogenesis in said subject, wherein the synaptic growth factor activating compound is administered intravenously as a continuous infusion. 
     
     
         25 . The method of  claim 24 , wherein the synaptic growth factor activating compound is administered intravenously as a continuous infusion every other week. 
     
     
         26 . The method of  claim 24 , wherein the synaptic growth factor activating compound is administered intravenously over 40-50 minutes. 
     
     
         27 . The method of  claim 24 , wherein the synaptic growth factor activating compound is administered intravenously over 40-50 minutes every other week. 
     
     
         28 . The method of  claim 24 , wherein the growth factor is selected from the group consisting of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and insulin-like growth factor (IGF). 
     
     
         29 . The method of  claim 24 , wherein the method increases BDNF levels. 
     
     
         30 . The method of  claim 24 , wherein the method prevents cognitive loss. 
     
     
         31 . The method of  claim 24 , wherein the method restores lost synapses. 
     
     
         32 . The method of  claim 24 , wherein the synaptic growth factor activating compound is combined with a non-growth factor PKC activator, wherein PKC is protein kinase C. 
     
     
         33 . The method of  claim 24 , wherein the subject is administered about 10 to about 100 μg of the synaptic growth factor activating compound. 
     
     
         34 . The method of  claim 24 , wherein the subject is not administered an N-methyl-D-aspartate (NMDA) receptor antagonist.

Join the waitlist — get patent alerts

Track US2021308099A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.